blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1729824

EP1729824 - PHOSPHOLIPID ANALOGS FOR THE TREATMENT OF CANCERS [Right-click to bookmark this link]
Former [2006/50]PHOSPHOLIPID ANALOGS FOR DIAGNOSIS AND TREATMENT OF CANCER
[2008/44]
StatusNo opposition filed within time limit
Status updated on  04.06.2010
Database last updated on 30.09.2024
Most recent event   Tooltip19.10.2012Lapse of the patent in a contracting state
New state(s): TR		published on 21.11.2012  [2012/47]
Applicant(s)For all designated states
Cellectar, Inc.
3301 Agriculture Drive
Madison, WI 53716 / US
[2009/15]
Former [2006/50]For all designated states
CELLECTAR, LLC
505 South Rosa Road
Madison WI 53719 / US
Inventor(s)01 / WEICHERT, Jamey
2765 Rosellen Avenue
Fitchburg, WI 53711-6506 / US
02 / LONGINO, Marc
311 Ridge View Trail
Verona, WI 53593-8353 / US
03 / PINCHUK, Anatoly
5212 Nannyberry Drive
Madison, WI 53711 / US
 [2007/15]
Former [2006/50]01 / WEICHERT, Jamey
2765 Rosellen Avenue
Fitchburg, WI 53711-6506 / US
02 / LONGINO, Marc
311 Ridge View Trail
Verona, WI 53593-8353 / US
03 / PINCHUK, Anatoly
2898 Mickelson Parkway
Madison, WI 53711-7301 / US
Representative(s)Wright, Robert Gordon McRae, et al
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks
Kent TN13 1XR / GB
[N/P]
Former [2009/44]Wright, Robert Gordon McRae, et al
Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks
Kent TN13 1XR / GB
Former [2009/15]Mays, Julie, et al
Barker Brettell LLP 10-12 Priests Bridge London
SW15 5JE / GB
Former [2006/50]Mays, Julie
Barker Brettell, 10-12 Priests Bridge
London SW15 5JE / GB
Application number, filing date05729873.902.03.2005
[2006/50]
WO2005US06681
Priority number, dateUS20040521166P02.03.2004         Original published format: US 521166 P
[2006/50]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2005084716
Date:15.09.2005
Language:EN
[2005/37]
Type: A2 Application without search report 
No.:EP1729824
Date:13.12.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 15.09.2005 takes the place of the publication of the European patent application.
[2006/50]
Type: B1 Patent specification 
No.:EP1729824
Date:29.07.2009
Language:EN
[2009/31]
Search report(s)International search report - published on:EP01.06.2006
ClassificationIPC:A61K51/04, A61P35/00, // A61K101/02
[2008/44]
CPC:
A61K51/04 (EP,KR,US); A61K51/0489 (US); A61K51/0408 (US);
A61P35/00 (EP); A61P43/00 (EP); C12Q1/34 (EP,US);
G01N33/57492 (EP,US); A61K49/0017 (US); C07F13/005 (US) (-)
Former IPC [2006/50]A61K51/04
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/50]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
LVNot yet paid
MKNot yet paid
YUNot yet paid
TitleGerman:PHOSPHOLIPID-ANALOGA FÜR DIE BEHANDLUNG VON KREBS[2008/44]
English:PHOSPHOLIPID ANALOGS FOR THE TREATMENT OF CANCERS[2008/44]
French:ANALOGUES PHOSPHOLIPIDIQUES POUR LE TRAITEMENT DE CANCERS[2008/44]
Former [2006/50]PHOSPHOLIPID-ANALOGA FÜR DIE DIAGNOSE UND BEHANDLUNG VON KREBS
Former [2006/50]PHOSPHOLIPID ANALOGS FOR DIAGNOSIS AND TREATMENT OF CANCER
Former [2006/50]ANALOGUES PHOSPHOLIPIDIQUES EN TANT QU'AGENTS DIAGNOSTIQUES E THERAPEUTIQUES, ET METHODES CORRESPONDANTES
Entry into regional phase29.09.2006National basic fee paid 
29.09.2006Designation fee(s) paid 
29.09.2006Examination fee paid 
Examination procedure29.09.2006Examination requested  [2006/50]
27.11.2006Amendment by applicant (claims and/or description)
26.04.2007Despatch of a communication from the examining division (Time limit: M06)
06.11.2007Reply to a communication from the examining division
09.06.2008Cancellation of oral proceeding that was planned for 11.06.2008
09.06.2008Minutes of oral proceedings despatched
11.06.2008Date of oral proceedings
11.06.2008Date of oral proceedings (cancelled)
16.06.2008Despatch of a communication from the examining division (Time limit: M02)
15.08.2008Reply to a communication from the examining division
09.10.2008Communication of intention to grant the patent
19.02.2009Fee for grant paid
19.02.2009Fee for publishing/printing paid
23.03.2009Despatch of a communication from the examining division (Time limit: M02)
21.05.2009Reply to a communication from the examining division
Divisional application(s)EP08010321.1  / EP2044960
EP08020805.1  / EP2044961
Opposition(s)03.05.2010No opposition filed within time limit [2010/27]
Fees paidRenewal fee
21.02.2007Renewal fee patent year 03
27.03.2008Renewal fee patent year 04
26.03.2009Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT29.07.2009
BE29.07.2009
CY29.07.2009
CZ29.07.2009
EE29.07.2009
FI29.07.2009
LT29.07.2009
PL29.07.2009
RO29.07.2009
SI29.07.2009
SK29.07.2009
TR29.07.2009
BG29.10.2009
GR30.10.2009
IS29.11.2009
PT29.11.2009
HU30.01.2010
MC31.03.2010
[2012/47]
Former [2012/42]AT29.07.2009
BE29.07.2009
CY29.07.2009
CZ29.07.2009
EE29.07.2009
FI29.07.2009
LT29.07.2009
PL29.07.2009
RO29.07.2009
SI29.07.2009
SK29.07.2009
BG29.10.2009
GR30.10.2009
IS29.11.2009
PT29.11.2009
HU30.01.2010
MC31.03.2010
Former [2012/37]AT29.07.2009
BE29.07.2009
CY29.07.2009
CZ29.07.2009
EE29.07.2009
FI29.07.2009
LT29.07.2009
PL29.07.2009
RO29.07.2009
SI29.07.2009
SK29.07.2009
BG29.10.2009
GR30.10.2009
IS29.11.2009
PT29.11.2009
MC31.03.2010
Former [2010/46]AT29.07.2009
BE29.07.2009
CZ29.07.2009
EE29.07.2009
FI29.07.2009
LT29.07.2009
PL29.07.2009
RO29.07.2009
SI29.07.2009
SK29.07.2009
BG29.10.2009
GR30.10.2009
IS29.11.2009
PT29.11.2009
MC31.03.2010
Former [2010/25]AT29.07.2009
BE29.07.2009
CZ29.07.2009
EE29.07.2009
FI29.07.2009
LT29.07.2009
PL29.07.2009
RO29.07.2009
SI29.07.2009
SK29.07.2009
BG29.10.2009
IS29.11.2009
PT29.11.2009
Former [2010/23]AT29.07.2009
CZ29.07.2009
EE29.07.2009
FI29.07.2009
LT29.07.2009
PL29.07.2009
RO29.07.2009
SI29.07.2009
SK29.07.2009
BG29.10.2009
IS29.11.2009
PT29.11.2009
Former [2010/20]AT29.07.2009
EE29.07.2009
FI29.07.2009
LT29.07.2009
PL29.07.2009
SI29.07.2009
BG29.10.2009
IS29.11.2009
PT29.11.2009
Former [2010/17]AT29.07.2009
FI29.07.2009
LT29.07.2009
PL29.07.2009
SI29.07.2009
BG29.10.2009
IS29.11.2009
PT29.11.2009
Former [2010/12]AT29.07.2009
FI29.07.2009
LT29.07.2009
PL29.07.2009
SI29.07.2009
IS29.11.2009
Cited inInternational search[X]US5369097  (SALARI HASSAN [US], et al) [X] 5,6,10 * column 17, line 62 - column 18, line 46 * * tables 18,19 *;
 [XY]US5795561  (COUNSELL RAYMOND E [US], et al) [X] 14 * column 1, lines 24-55 * * column 3, lines 24-62 * * column 4, line 57 - column 5, line 15 * * column 15, lines 15-54 * * figures 4-7 * [Y] 15-17;
 [XY]US2002065429  (COUNSELL RAYMOND E [US], et al) [X] 1-13 * abstract * * paragraphs [0006] , [0009] - [0016] * * paragraphs [0025] - [0028] * * example 5, paragraph [0053] * * paragraphs [0054] - [0058] * * example 7, paragraph [0067] * * examples 6-8 * * claims * * figures 5C,7B,7C,8A,8C * [Y] 15-17;
 [D]US6417384  (COUNSELL RAYMOND E [US], et al);
 [XY]  - COUNSELL, R. E. ET AL, "Synthesis and evaluation of a radioiodinated phospholipid ether analog (NM-404) for diagnostic imaging of prostate cancer", ISOTOPE PRODUCTION AND APPLICATIONS IN THE 21ST CENTURY, PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON ISOTOPES, 3RD, VANCOUVER, BC, CANADA, SEPT. 6-10, 1999 , MEETING DATE 1999, 163-166. EDITOR(S): STEVENSON, NIGEL R. PUBLISHER: WORLD SCIENTIFIC P, (2000), XP008054467 [X] 1-4 * the whole document * [Y] 15-17
 [X]  - WEICHERT J.P. ET AL., "Evaluation of 125I-NM404 in a Spontaneous Murine Pancreatic Adenocarcinoma Model", 2ND ANNUAL MEETING OF THE SOCIETY OF MOLECULAR IMAGING, SAN FRANCISCO, USA; August 15-18, 2003, (200308), URL: http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={A174CAD4-4C67-46EE-97CA-B94654C77699}&MKey={4C56C7C9-3CB4-404E-A0C1-3F37525A5245}&AKey={A4C6DD8F-4BF2-400D-97ED-20C14381CDBB}&SKey={0AAB7B18-F58E-4226-A5D5-755F3585A60F}, (20060127), XP002365137 [X] 1-4 * presentation number 304, abstract *
 [X]  - ZASADNY K R ET AL, "Predicted dosimetry for I-131-NM-404, a phospholipid ether agent for tumor imaging and possible therapy", JOURNAL OF NUCLEAR MEDICINE, & 46TH ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE; LOS ANGELES, CALIFORNIA, USA; JUNE 6-10, 1999, (199905), vol. 40, no. 5 SUPPL., ISSN 0161-5505, page 39P, XP008059114 [X] 1-13 * the whole document *
 [X]  - WEICHERT JP ET AL, "Specificity of NM404 for Hyperplasia versus Neoplasia in the ApcMin/+ Endogenous Mammary Adenocarcinoma Model", 2ND ANNUAL MEETING OF THE SOCIETY OF MOLECULAR, SAN FRANCISCO, USA; August 15-18, 2003, (200308), URL: http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={175C0489-C808-47DF-B4EF-5CF57EE52265}&MKey={4C56C7C9-3CB4-404E-A0C1-3F37525A5245}&AKey={A4C6DD8F-4BF2-400D-97ED-20C14381CDBB}&SKey={0AAB7B18-F58E-4226-A5D5-755F3585A60F}, (20060127), XP002365140 [X] 1-17 * presentation number 3005, abstract *
 [DX]  - PLOTZKE K P ET AL, "Selective localization of radioiodinated alkylphosphocholine derivatives in tumors", NUCLEAR MEDICINE AND BIOLOGY 1992 UNITED KINGDOM, (1992), vol. 19, no. 7, ISSN 0883-2897, pages 765 - 773, XP002365138 [DX] 1 * page 772, column 2, paragraph 2 * * figure 7 *

DOI:   http://dx.doi.org/10.1016/0883-2897(92)90138-O
 [DX]  - PLOTZKE K P ET AL, "Selective localization of a radioiodinated phospholipid ether analog in human tumor xenografts", JOURNAL OF NUCLEAR MEDICINE 1993 UNITED STATES, (1993), vol. 34, no. 5, ISSN 0161-5505, pages 787 - 792, XP008059115 [DX] 1 * abstract * * figures 2,4 * * table 2 *
 [DX]  - RAMPY M A ET AL, "Biological disposition and imaging of a radioiodinated alkylphosphocholine in two rodent models of breast cancer", JOURNAL OF NUCLEAR MEDICINE 1996 UNITED STATES, (1996), vol. 37, no. 9, ISSN 0161-5505, pages 1540 - 1545, XP008059146 [DX] 1 * abstract * * figure 5 *
 [X]  - TERWOGT J M M ET AL, "Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer", BRITISH JOURNAL OF CANCER 1999 UNITED KINGDOM, (1999), vol. 79, no. 7-8, ISSN 0007-0920, pages 1158 - 1161, XP002365139 [X] 5,6,10 * the whole document *

DOI:   http://dx.doi.org/10.1038/sj.bjc.6690184
 [IX]  - BERDEL W E ET AL, "Daily oral miltefosine (hexadecylphosphocholine) in patients with advanced non-small cell lung cancer. A phase II study", ONKOLOGIE 1992 GERMANY, (1992), vol. 15, no. 3, ISSN 0378-584X, pages 238 - 242, XP008059103 [IX] 5,6,10 * abstract *
 [IX]  - BECHER R ET AL, "Phase II trial of orally administered miltefosine in advanced colorectal cancer", ONKOLOGIE 1993 GERMANY, (1993), vol. 16, no. 1, ISSN 0378-584X, pages 11 - 15, XP008059036 [IX] 5,6,10 * abstract *
 [DXY]  - COUNSELL R E ET AL, "TUMOR VISUALIZATION WITH A REDIOIODINATED PHOSPHOLIPID ETHER", JOURNAL OF NUCLEAR MEDICINE, SOCIETY OF NUCLEAR MEDICINE, RESTON, VA, US, (19900301), vol. 31, no. 3, ISSN 0161-5505, pages 332 - 336, XP000128750 [DX] 14 * page 333 - page 334, section "results" * * figures 4,5 * [Y] 15-17
 [IX]  - OSHIMOTO HIROKAZU ET AL, "Increased activity and expression of phospholipase D2 in human colorectal cancer.", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (2003), Database accession no. PREV200300566956, XP002365146 [IX] 18-21 * abstract *
    [ ] - ONCOLOGY RESEARCH, (2003), vol. 14, no. 1, ISSN 0965-0407, pages 31 - 37
 [IX]  - MIN DO SIK ET AL, "Neoplastic transformation and tumorigenesis associated with overexpression of phospholipase D isozymes in cultured murine fibroblasts", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (200110), Database accession no. PREV200100523916, XP002365147 [IX] 18-21 * abstract *
    [ ] - CARCINOGENESIS (OXFORD), (200110), vol. 22, no. 10, ISSN 0143-3334, pages 1641 - 1647
 [IX]  - NOH DONG-YOUNG ET AL, "Overexpression of phospholipase D1 in human breast cancer tissues", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (20001220), Database accession no. PREV200100047408, XP002365186 [IX] 18-21 * abstract *
    [ ] - CANCER LETTERS, (20001220), vol. 161, no. 2, ISSN 0304-3835, pages 207 - 214
 [DA]  - RAMPY M A ET AL, "Synthesis and biological evaluation of radioiodinated phospholipid ether stereoisomers", JOURNAL OF MEDICINAL CHEMISTRY 1995 UNITED STATES, (1995), vol. 38, no. 16, ISSN 0022-2623, pages 3156 - 3162, XP002350685 [DA] 18-21 * abstract * * page 3157 * * page 3158, last paragraph - page 3160 * * tables 3,4 *

DOI:   http://dx.doi.org/10.1021/jm00016a019
 [PX]  - WEICHERT J.P. ET AL, "Initial Clinical Imaging Results with NM404 in Non-Small Cell Lung Cancer", MOLECULAR IMAGING, & 3RD ANNUAL MEETING OF THE SOCIETY OF MOLECULAR IMAGING, ST LOUIS; September 9-12, 2004, vol. 3, no. 3, (200407), pages 269 - 270, URL: http://mitpress.mit.edu/journals/pdf/moim_3_3_178_0.pdf, (20060127), XP002365141 [PX] 1-4 * presentation number 337, abstract *
 [PX]  - LONGINO M.A. ET AL, "Tumor Selective Retention of NM404 - Involvement of Phospholipase D", MOLECULAR IMAGING, & 3RD ANNUAL MEETING OF THE SOCIETY OF MOLECULAR IMAGING, ST LOUIS, USA; September 9-12, 2004, vol. 3, no. 3, (200407), page 257, URL: http://mitpress.mit.edu/journals/pdf/moim_3_3_178_0.pdf, (20060127), XP002365142 [PX] 18-21 * presentation number 290, abstract *
Examination   - JHANWAR Y.S.; DIVGI C., "Current Status of Therapy of Solid Tumors", THE JOURNAL OF NUCLEAR MEDICINE, (200501), vol. 46, pages 141S - 150S
    - MURRAY J.L. ET AL, "Phase II Radioimmunotherapy rial with 131I-CC49 in Colorectal Cancer", CANCER SUPPLEMENT, (19940201), vol. 73, no. 3, pages 1057 - 1066
    - MIYAGAWA T. ET AL, "Imaging of HSV-tk Reporter Gene Expression: Comparison between [18F]FEAU, [18F]FFEAU, and Other Imaging Probes", THE JOURNAL OF NUCLEAR MEDICINE, (200804), vol. 49, no. 4, pages 637 - 648
    - WANG H. ET AL, "Molecular Imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for Monitoring Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Prodrug Activation Gene Therapy of Cancer", THE JOURNAL OF NUCLEAR MEDICINE, (200607), vol. 47, no. 7, pages 1161 - 1171
by applicantUS4925649
 US4965391
 US5087721
 US5347030
 US6255519
 US6417384
    - J CLIN ONCOL, (1999), vol. 17, no. 10, pages 3201 - 3206
    - AHUJA V ET AL., "The prognostic significance of fluorodexoyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma", CANCER, (1998), vol. 83, no. 5, pages 918 - 924
    - SEFTON, CRC CRIT. REF. BIOMED. ENG., (1987), vol. 14, page 201
    - BUCHWALD ET AL., SURGERY, (1980), vol. 88, page 507
    - SAUDEK ET AL., N. ENGL. J. MED., (1989), vol. 321, page 574
    - GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, (1984), vol. 2, pages 115 - 138
    - LANGER, SCIENCE, (1990), vol. 249, pages 1 527 - 1 533
    - TREAT ET AL., Liposomes in the Therapy of Infectious Disease and Cancer, LISS, (1989), pages 353 - 365
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.